In earlier studies, one in six adults had overactive bladder which may impair quality of life. However, earlier studies have either not been population-based or have suffered from methodological limitations. Our aim was to assess the prevalence of overactive bladder symptoms, based on a representative study population and using consistent definitions and exclusions.
The aim of the study was to assess the age-standardized prevalence of overactive bladder defined as urinary urgency, with or without urgency incontinence, usually with urinary frequency and nocturia in the absence of urinary tract infection or other obvious pathology. In 2003–2004, a questionnaire was mailed to 6,000 randomly selected Finns aged 18–79 years who were identified from the Finnish Population Register Centre. Information on voiding symptoms was collected using the validated Danish Prostatic Symptom Score, with additional frequency and nocturia questions. Corrected prevalence was calculated with adjustment for selection bias due to non-response. The questionnaire also elicited co-morbidity and socio-demographic information. Of the 6,000 subjects, 62.4% participated. The prevalence of overactive bladder was 6.5% (95% CI, 5.5% to 7.6%) for men and 9.3% (CI, 7.9% to 10.6%) for women. Exclusion of men with benign prostatic hyperplasia reduced prevalence among men by approximately one percentage point (to 5.6% [CI, 4.5% to 6.6%]). Among subjects with overactive bladder, urgency incontinence, frequency, and nocturia were reported by 11%, 23%, and 56% of men and 27%, 38%, and 40% of women, respectively. However, only 31% of men and 35% of women with frequency, and 31% of subjects of both sexes with nocturia reported overactive bladder.
Citation: Tikkinen KA, Tammela TL, Rissanen AM, Valpas A, Huhtala H, Auvinen A (2007) Is the Prevalence of Overactive Bladder Overestimated? A Population-Based Study in Finland. PLoS ONE 2(2): e195. doi:10.1371/journal.pone.0000195
Academic Editor: Stephan Madersbacher, Ludwig Boltzmann Institute for Urological Oncology, Austria
Received: December 13, 2006; Accepted: January 8, 2007; Published: February 7, 2007
Copyright: © 2007 Tikkinen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was funded by a grant from the Medical Research Fund of the Tampere University Hospital, and an unrestricted grant was accepted from Pfizer to cover the mailing and printing costs of questionnaires. The work of the corresponding author was funded by unrestricted grants from the Emil Aaltonen Foundation, the Lilly Foundation, the Medical Research Fund of the Tampere University Hospital, the Research Foundation of Orion Corporation, and the Tampere University Foundation. The funding sources had no role in study design, in the collection, analysis, and interpretation of data, in the writing of the report, and in the decision to submit the paper for publication. The authors' work was independent of the funders. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Competing interests: Aila Rissanen, Heini Huhtala, and Anssi Auvinen declare no conflict of interest, whereas Kari Tikkinen declares honorarium for Pfizer, Teuvo Tammela consultancies and honoraria for Pfizer, UCB and Astellas Pharma, and Antti Valpas consultanties for Pfizer and honoraria for Astellas Pharma.
Research on urinary storage problems has focused on incontinence in women, but during recent years other urinary storage problems (urgency, frequency, and nocturia) and their treatment among both sexes has commanded attention worldwide . According to the International Continence Society, overactive bladder is a symptom-defined condition characterized by urinary urgency, with or without urgency incontinence, usually with urinary frequency and nocturia. The term overactive bladder is appropriate if there is no proven infection or other obvious pathology .
Overactive bladder is a poorly understood disorder . In earlier reports, overactive bladder impaired quality of life , , was underdiagnosed and undertreated , –, and cost more than $9 billion in the United States in 2000 , . However, the value of current overactive bladder treatment with antimuscarinics (with an increasing market [11% annual growth] worldwide of more than $2.2 billion in 2005 ) was questioned by the Cochrane Review .
Most earlier studies on overactive bladder have reported a prevalence of 10%–20% –, , –, the most widely cited studies estimating prevalence of overactive bladder as one in six , . Some studies have reported prevalence as high as 30% to 53% , , while one showed only 8% , and one as low as 2% . Unfortunately, all these studies have had methodological limitations , , , , , – or have not been population-based , , , .
We assessed the prevalence of overactive bladder in a population-based study of subjects of both sexes aged 18–79 years.
Between November 2003 and February 2004, a questionnaire was mailed to a random sample of 3,000 men and 3,000 women aged 18–79 years drawn from the Finnish Population Register Center. Stratification by age was used in subject selection, with oversampling of the younger age groups to achieve a similar number of subjects with urgency/overactive bladder even in age groups with lower prevalence of urgency/overactive bladder (Table S1). We selected the target level of accuracy so that, given a true prevalence of 15%, we could exclude a prevalence of 10% or lower. Information on voiding symptoms was collected using the validated Danish Prostatic Symptom Score (Table 1) . The questionnaire included items related to physician-diagnosed co-morbidity (such as gynecological, internal, mental, musculoskeletal, neurological, and/or urological conditions), prescribed medication (over the last 3 months) and socio-demographic factors (such as marital, educational and employment status). Information on pregnancy was based on both questionnaire and data from the Finnish Population Register Center which also provided information on puerperium and urbanity. Questionnaires were first mailed in late November 2003, with reminders a month later. To persons who did not respond, final questionnaire was sent in February 2004. The last questionnaires were returned in June 2004. In accordance with Finnish regulations on questionnaire surveys, an exemption from ethical review was granted by the ethical committee of Tampere University Hospital (Tampere, Finland).
Exclusions and definitions
In the first analysis (Urgency analysis), we assessed the prevalence of urgency in adult population without applying any exclusion criteria (Figure 1). In the main analysis (Overactive bladder analysis), we assessed the prevalence of overactive bladder in adult population excluding those with physician-diagnosed: 1) chronic or acute urinary tract infection (in the past 2 weeks); 2) genitourinary cancer (excluding renal); or 3) contracted bladder (due to radiation or painful bladder syndrome), also 4) prescribed loop diuretics; and 5) pregnant or puerperal women, with puerperium defined as 6 weeks after childbirth (Table 2). In the third analysis (OAB without BPH analysis), in addition to above mentioned exclusions (of Overactive bladder analysis), we excluded men reporting physician-diagnosed benign prostatic hyperplasia. We performed a fourth analysis (All OAB symptoms analysis), to assess the relationship of all symptoms of overactive bladder with the same exclusions as used in the Overactive bladder analysis (Figure 1).
Flow chart of the study in Finland, 2003–2004. * OAB, overactive bladder; BPH, benign prostatic hyperplasia; SD, standard deviation.
The urgency question from the validated Danish Prostatic Symptom Score was used to assess the prevalence of urgency and overactive bladder . Overactive bladder with or without urgency incontinence classification was subdivided into overactive bladder cases based on the urinary urgency incontinence question of the Danish Prostatic Symptom Score. The mean daily number of voids was used for urinary frequency classification, whereas responses to nocturia questions from the Danish Prostatic Symptom Score and American Urological Association Symptom Index were combined , . The Danish Prostatic Symptom Score questionnaire was applied for the past 2 weeks, while frequency question and nocturia question of American Urological Association Symptom Index pertained to the past month (Table 1).
Subjects were stratified into 10-year age groups (18–29, 30–39, 40–49, 50–59, 60–69, and 70–79 years). The age-standardized prevalence was calculated using the general population of Finland (end of year 2003) by the Finnish Population Register Centre  (and the European standard population ). Binomial regression with identity link was used with presence of overactive bladder as outcome for extrapolation of age-specific prevalence of overactive bladder among people aged 80 years or more. All confidence intervals were likelihood-based. Confidence Interval Analysis 2.0.0 software (Trevor Bryant, University of Southampton, United Kingdom) was used for calculating age-standardized prevalences and confidence intervals (CI). Other analyses were performed using the Stata 9 (StataCorp LP, College Station, United States).
Adjustment for selection bias due to non-response was made for each symptom and combination of symptom (urgency, overactive bladder with or without urgency incontinence, frequency, and nocturia) after possible exclusions. First, prevalence of symptoms was calculated by mailing round (defined by date of questionnaire completion). As the prevalence of symptoms was lower in the subsequent than in the first round responses, the prevalence among non-participants (of the eligible study population) was assumed to be similar to the late responders, using formula:where P is prevalence of symptom (urgency, overactive bladder with or without urgency incontinence, frequency or nocturia).
Hence, based on the number of non-participants and prevalence of symptoms, we calculated the number of subjects with each symptom (and combinations in the All OAB symptoms analysis). The corrected prevalence of symptom was calculated using the formula:where P is prevalence of symptom (or combination of symptom) and N is number of subjects.
Concerning analyses for corrected prevalence of symptoms, we also performed an analysis excluding the same proportion of subjects among non-participants as we had done among participants, but the results did not materially change.
Of the 6,000 subjects approached for the study, 3,727 (62.4%) participated; 23 were unavailable because of serious disability or disease, death, or emigration (Figure 1). Of all participants, 98.5% (n = 3670) responded to the Danish Prostatic Symptom Score urgency question (Urgency analysis). For the assessment of overactive bladder prevalence (Overactive bladder analysis), we excluded 210 participants (Table 2). Most of the included participants (94.0%) also gave the date of questionnaire completion (Table S1). To assess the effect of benign prostatic hyperplasia on overactive bladder (OAB without BPH analysis), we further excluded 114 men. For comparison of all symptoms of overactive bladder, every question on urgency, urgency incontinence, frequency, and nocturia was answered by 95.2% of subjects (Figure 1).
After age-standardization (to the Finnish general population), prevalence of urgency was 7.0% (95% CI, 5.9% to 8.1%) for men and 10.3% (CI, 8.9% to 11.6%) for women. The age-standardised prevalence of overactive bladder was 6.5% (CI, 5.5% to 7.6%) for men and 9.3% (CI, 7.9% to 10.6%) for women (Figure 2). Exclusion of men with benign prostatic hyperplasia decreased the prevalence of overactive bladder among men to 5.6% (CI, 4.5% to 6.6%). The effect of benign prostatic hyperplasia on the prevalence of overactive bladder was strongest in elderly with the prevalence decreasing from 17.5% to 13.5% at age 60–69 years and from 17.6% to 14.0% at age 70–79 years after further exclusion of men with benign prostatic hyperplasia.
The prevalence of overactive bladder in Finland, 2003–2004. The blue bars indicate men with overactive bladder and the red bars women with overactive bladder. Age-standardization was performed using the general population .
In general, overactive bladder was slightly more common among women than men after age-standardization (Figure 2). It was more common among women in younger ages while among men it was more common in those aged 60 years and above. Among men, the sharpest increase occurred at age 60–69 years while among women the increase was more steady. The mean increases in prevalence of overactive bladder were 2.4 percentage point (CI, 1.9%-point to 3.0%-point) per 10-year age group for men and 1.9 percentage point (CI, 1.2%-point to 2.6%-point) per 10 years for women. There was no statistically significant departure from linearity in either sex (Figure 2).
In the All OAB symptoms analysis (Figure 3), urgency incontinence was reported by 11% of men and 27% of women among those with overactive bladder. Urinary frequency was reported by 23% of men and 38% of women with overactive bladder whereas the corresponding figures for nocturia were 56% and 40%. On the other hand, even though subjects with overactive bladder reported more frequency and nocturia than subjects without overactive bladder, only 31% of men and 35% of women with frequency, and 31% of subjects among both sexes with nocturia reported overactive bladder (Figure 3).
Age-standardized prevalence of overactive bladder symptoms among Finnish people aged 18–79 years, 2003–2004. The red circle represents subjects with overactive bladder without urgency incontinence excluding the area of the red oval representing subjects with overactive bladder with urgency incontinence. The blue circle represents subjects with urinary frequency (defined as more than eight voids per day) and the green circle nocturia (defined as more than one void per night). Age-standardization was performed using the general population .
Without corrections for non-response, urgency was reported by 7.9% (CI, 6.5% to 9.3%) of men and 10.7% (CI, 9.0% to 12.3%) of women after age-standardization. The corresponding figures for overactive bladder were 7.3% (CI, 5.9% to 8.7%) for men and 9.7% (CI, 8.0% to 11.3%) for women. Further exclusion of men with benign prostatic hyperplasia decreased the non-corrected prevalence of overactive bladder to 6.3% (CI, 4.8% to 7.7%) among men aged 18–79 years.
In our study, the prevalence of overactive bladder was 6.5% for men and 9.3% for women, i.e. no more than 8% of adult population aged 18–79 years had overactive bladder. Subjects with overactive bladder reported more frequency and nocturia than those without overactive bladder, but the majority of subjects with frequency, or nocturia did not report overactive bladder.
The reported prevalence of overactive bladder has varied widely in earlier studies due to differences in symptom assessment, study population, data collection, and definition of overactive bladder including exclusion criteria. Most other studies have reported greater prevalence of overactive bladder than found in our study –, –. Some –, – but not all studies  have also reported more urgency incontinence among subjects with overactive bladder than we found.
The definition of a symptom-defined disorder, such as overactive bladder, has a major impact on outcome . We used the overactive bladder definition of International Continence Society, with urgency (defined as sudden compelling desire to void) as a sufficient criterion for overactive bladder . This definition is idealistic and ambiguous. The qualitative definition disregarding severity or symptom bother makes it difficult to apply. The classification of a symptom (including the time period during which the occurrence of symptoms is asked) strongly influences the result, due in part to fluctuating character and very high remission rates of lower urinary tract symptoms, including urgency . We asked about urgency in the last 2 weeks with four response option: if urgency was reported “never” or “rarely”, the subject was classified as normal, while “often” and “always” were regarded as abnormal. Our classification of urgency differed slightly from the Austrian study, where a five-point scale was used for the last 4 weeks and subjects who “occasionally” had urgency were also defined as abnormal . Similarly, in the Chinese community-based study, women who reported urgency “occasionally” were regarded abnormal but only in the presence of other symptoms (with criteria every 3 hour for frequency, twice per night for nocturia, and once a week or less frequent for urge incontinence) . In the US study, those who reported four or more urgency episodes during the last 4 weeks and who also reported more than eight voids per day, or at least one coping strategy were classified as abnormal . Some studies asked symptoms over a very long or unspecified time , , ,  whereas some did not exactly describe symptom classification, questions asked, or time concerning the symptom question , , , , . Overall, in all symptom-defined disorders (including overactive bladder), defining very mild/rare symptoms as pathological blurs the distinction between mild and severe, causing a considerable risk of encouraging healthy people to perceive themselves as sick .
In the standardization report , the current definition of overactive bladder includes “…usually with frequency and nocturia.”, and those symptoms are defined as complaints without any severity assessment. We defined frequency as more than 8 voids per day and nocturia as more than one void per night (as in some earlier reports –, ) while those definitions are presumably clinically more relevant based on prevalences of frequency and nocturia in earlier studies , , , . On the other hand, the definition of frequency or nocturia has no effect on the prevalence of overactive bladder when based on the current definition.
According to the standardization report , for the diagnosis of overactive bladder subjects with “urinary infection or other obvious pathology” should be excluded. Identification of overactive bladder without excluding known reasons causing urgency can result in overestimate of prevalence. We excluded subjects with urinary tract infection, genitourinary cancer, contracted bladder, or loop diuretics, as well as pregnant and puerperal women. In addition, we performed an analysis excluding men with benign prostatic hyperplasia as its effect on overactive bladder is unclear . Some earlier studies did not report any exclusion criteria , –, , –, or excluded only subjects with urinary tract infection . In the Austrian and Brazilian studies , , exclusions were slightly broader (for example, diabetes) than in our study and in the US study  even more extensive (including diabetes, congestive heart failure, and excessive fluid intake). In the Austrian study, exclusions were performed for subjects with urgency, not for the whole study sample.
Several articles have been published on the prevalence of overactive bladder (English-language MEDLINE and PubMed search to December 2006). However, many of these studies have not been population-based , , , , whereas the population-based studies , , , , , – have failed to: 1) apply the current definition of overactive bladder , , , , , , 2) report any exclusions , , , , 3) include all adult ages , , , , , 4) include both sexes , 5) report response rate or non-participants , , , or 6) achieve good response rate , , ,  (Table 3). Furthermore, none of the earlier studies used non-response analysis to adjust for selection bias. On the other hand, as long as the symptom definition of overactive bladder is more like a description without any severity or bother assessment, there is no absolutely correct way to study the epidemiology of overactive bladder.
We used postal questionnaires to assess both the prevalence of urinary symptoms and co-morbidity. Overactive bladder is a symptom-defined condition requiring self-report. Mailed questionnaires reflect urodynamics better than interview-assisted questionnaire responses . Furthermore, mailed questionnaires provide more reliable information than telephone surveys in several aspects, including higher participation . Telephone surveys have commonly been used, including the most cited figures , , , .
Even though most studies reported higher prevalence estimates than ours, the differences can be readily explained by dissimilarities in study procedures. For instance, Milsom and colleagues stated in their multinational study that 16.6% had overactive bladder . They did not use the current definition of overactive bladder and excluded only subjects with urinary tract infection. In their study (all subjects at least 40 years old) only 54% of subjects with overactive bladder reported urgency corresponding approximately to 9.0% prevalence of urgency. Hence, based on their study population 9.0% prevalence of overactive bladder would also be overestimated due to age distribution and absence of other exclusion criteria and non-response analysis. This estimate concurs with our results.
Of the Finnish adult population, 5% are aged 80 years or more . As our sample did not include this age group, we extrapolated the prevalence rates for people aged 80 years or more. Based on extrapolated prevalence rates of overactive bladder among this age group (20.0% for men and 17.5% for women), we calculated age-standardized prevelance of overactive bladder for men (6.9%) and women (9.8%). Adjustment for people aged 80 years or more did not materially change prevalence rates as they were within the confidence limits of our estimates indicating that one in twelve (8.4%) had overactive bladder in the general population. However, our study population was Caucasian, which may diminish generalizability to other ethnicities. Most reported studies also used a study population that was mainly or totally Caucasian without proper comparison of prevalence of overactive bladder between different ethnicities –, , , , . Consequently, there is a need to examine the effect of ethnic differences on the prevalence of overactive bladder.
Our aim was to obtain a generalizable, unbiased estimate of the prevalence of overactive bladder in both genders. Our study population from youth to old age was representative of Finnish adults in terms of socio-demographic and anthropometric factors ,  and included people aged 18–79 years. Age-standardization was used to improve comparability with other studies and generalizability to other populations. Current population distribution of Finland was used so as not to underestimate prevalences. We calculated corresponding figures also using European standard population , but as the age structure was younger in that, the prevalence rates were slightly lower (not reported). To further improve the generalizability, we estimated corrected prevalence of overactive bladder with adjustment for people aged at least 80 years. After adjustment for people aged 80 years or more, the results remained substantially the same. A good response rate was achieved, but to further improve the validity, we estimated the corrected prevalence of overactive bladder with adjustment for selection bias due to non-response. We corrected prevalence for selection bias on the assumption that overactive bladder was equally common among non-responders and in late responders. The corrected estimate was smaller, indicating that naїve analysis overestimates prevalence.
Our results suggest that the prevalence of overactive bladder has been overestimated so that the true prevalence is approximately half of that proposed earlier. Overactive bladder affects approximately one out of twelve adults of Caucasian origin.
Number of subjects in different analyses and in overactive bladder analysis.
(0.07 MB DOC)
We thank Drs. Hai-Tao Jin, and Tapani Keränen for their valuable comments on earlier versions of the manuscript, and Virginia Mattila for language revision.
Other: Designed the study: KT TT AA. Peformed further statistical analyses: KT HH AA. Contributed to the interpretation of the findings and formulation of the report: KT TT AR AV HH AA. Wrote the first draft of the manuscript: KT. Contributed to revision of the manuscript: KT TT AR AV HH AA.
- 1. Ouslander JG (2004) Management of overactive bladder. N Engl J Med 350(8): 786–799.
- 2. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, et al. (2002) The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 21(2): 167–178.
- 3. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, et al. (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87(9): 760–766.
- 4. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, et al. (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20(6): 327–336.
- 5. Temml C, Heidler S, Ponholzer A, Madersbacher S (2005) Prevalence of the overactive bladder syndrome by applying the International Continence Society definition. Eur Urol 48(4): 622–627.
- 6. Homma Y, Yamaguchi O, Hayashi K, Neurogenic Bladder Society Committee (2005) An epidemiological survey of overactive bladder symptoms in Japan. BJU Int 96(9): 1314–1318.
- 7. Teloken C, Caraver F, Weber FA, Teloken PE, Moraes JF, et al. (2006) Overactive bladder: Prevalence and implications in Brazil. Eur Urol 49(6): 1087–1092.
- 8. Moorthy P, Lapitan MC, Quek PL, Lim PH (2004) Prevalence of overactive bladder in Asian men: An epidemiological survey. BJU Int 93(4): 528–531.
- 9. Corcos J, Schick E (2004) Prevalence of overactive bladder and incontinence in Canada. Can J Urol 11(3): 2278–2284.
- 10. Lapitan MC, Chye PL, Asia-Pacific Continence Advisory Board (2001) The epidemiology of overactive bladder among females in Asia: A questionnaire survey. Int Urogynecol J Pelvic Floor Dysfunct 12(4): 226–231.
- 11. Hu TW, Wagner TH (2005) Health-related consequences of overactive bladder: An economic perspective. BJU Int 96 Suppl 143–45.
- 12. IMS World Review (2006) http://www.imsportal.com (accessed June 1, 2006).
- 13. Hay-Smith J, Herbison P, Ellis G, Moore K (2002) Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev (3)(3): CD003781.
- 14. Chen GD, Lin TL, Hu SW, Chen YC, Lin LY (2003) Prevalence and correlation of urinary incontinence and overactive bladder in Taiwanese women. Neurourol Urodyn 22(2): 109–117.
- 15. Yu HJ, Liu CY, Lee KL, Lee WC, Chen TH (2006) Overactive bladder syndrome among community-dwelling adults in Taiwan: Prevalence, correlates, perception, and treatment seeking. Urol Int 77(4): 327–333.
- 16. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, et al. (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 50(6): 1306–1315.
- 17. Zhang W, Song Y, He X, Huang H, Xu B, et al. (2006) Prevalence and risk factors of overactive bladder syndrome in Fuzhou Chinese women. Neurourol Urodyn 25(7): 717–721.
- 18. Parazzini F, Lavezzari M, Arbitani W (2002) Prevalence of overactive bladder and urinary incontinence. J Fam Pract 51(12): 1072–1075.
- 19. Schou J, Poulsen AL, Nordling J (1993) The value of a new symptom score (DAN-PSS) in diagnosing uro-dynamic infravesical obstruction in BPH. Scand J Urol Nephrol 27(4): 489–492.
- 20. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, et al. (1992) The American Urological Association symptom index for benign prostatic hyperplasia. the measurement committee of the American Urological Association. J Urol 148(5): 1549–57; discussion 1564.
- 21. The Population Register Centre (2004) Taskutieto fickfakta 2004. (In Finnish and Swedish). Helsinki, Finland: The Population Register Centre. http://www.vaestorekisterikeskus.fi/vrk/files.nsf/files/5EC4A1734BB7E9B8C2256ECC0039B42C/$file/Taskutieto+2004.pdf (accessed December 12, 2006).
- 22. dos Santos Silva I (1999) Cancer epidemiology: Principles and methods. Lyon, France: International Agency for Research on Cancer.
- 23. Ioannidis JP (2005) Why most published research findings are false. PLoS Med 2(8): e124.
- 24. Moller LA, Lose G, Jorgensen T (2000) Incidence and remission rates of lower urinary tract symptoms at one year in women aged 40–60: Longitudinal study. BMJ 320(7247): 1429–1432.
- 25. Moynihan R, Henry D (2006) The fight against disease mongering: Generating knowledge for action. PLoS Med 3(4): e191.
- 26. Swithinbank LV, Donovan JL, du Heaume JC, Rogers CA, James MC, et al. (1999) Urinary symptoms and incontinence in women: Relationships between occurrence, age, and perceived impact. Br J Gen Pract 49(448): 897–900.
- 27. Tikkinen KA, Tammela TL, Huhtala H, Auvinen A (2006) Is nocturia equally common among men and women? A population based study in Finland. J Urol 175(2): 596–600.
- 28. Khan MS, Chaliha C, Leskova L, Khullar V (2004) The relationship between urinary symptom questionnaires and urodynamic diagnoses: An analysis of two methods of questionnaire administration. BJOG 111(5): 468–474.
- 29. Armstrong BK, White E, Saracci R (1992) The personal interview. Principles of Exposure Measurement in Epidemiology. New York: Oxford University Press. pp. 190–193.
- 30. Tikkinen KA, Auvinen A, Huhtala H, Tammela TL (2006) Nocturia and obesity: A population-based study in Finland. Am J Epidemiol 163(11): 1003–1011.